Insider Selling: Five Prime Therapeutics Inc. (FPRX) Director Sells $449,589.00 in Stock
Five Prime Therapeutics Inc. (NASDAQ:FPRX) Director Peder Jensen sold 8,130 shares of the company’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $55.30, for a total transaction of $449,589.00. Following the transaction, the director now owns 4,065 shares of the company’s stock, valued at approximately $224,794.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) opened at 57.76 on Tuesday. Five Prime Therapeutics Inc. has a one year low of $28.01 and a one year high of $57.79. The firm has a 50-day moving average of $50.62 and a 200-day moving average of $46.62. The firm has a market capitalization of $1.57 billion, a P/E ratio of 6.45 and a beta of 4.48.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.21. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $7.50 million. Five Prime Therapeutics had a net margin of 64.94% and a return on equity of 59.23%. The firm’s revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.93) earnings per share. On average, equities analysts predict that Five Prime Therapeutics Inc. will post ($2.18) earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on FPRX shares. Leerink Swann reiterated an “outperform” rating and issued a $58.00 target price (up previously from $45.00) on shares of Five Prime Therapeutics in a research report on Monday, August 8th. Jefferies Group set a $60.00 target price on shares of Five Prime Therapeutics and gave the company a “buy” rating in a research report on Friday, August 5th. Credit Suisse Group AG reiterated a “buy” rating and issued a $54.00 target price on shares of Five Prime Therapeutics in a research report on Monday, November 7th. Finally, Citigroup Inc. started coverage on shares of Five Prime Therapeutics in a research report on Tuesday, October 25th. They issued a “buy” rating and a $65.00 target price for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Five Prime Therapeutics presently has an average rating of “Buy” and a consensus target price of $54.43.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. bought a new position in shares of Five Prime Therapeutics during the third quarter worth about $30,903,000. Acadian Asset Management LLC boosted its position in shares of Five Prime Therapeutics by 112.1% in the second quarter. Acadian Asset Management LLC now owns 1,094,368 shares of the company’s stock worth $45,250,000 after buying an additional 578,411 shares during the last quarter. FMR LLC boosted its position in shares of Five Prime Therapeutics by 24.1% in the second quarter. FMR LLC now owns 2,817,208 shares of the company’s stock worth $116,492,000 after buying an additional 547,808 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Five Prime Therapeutics during the second quarter worth about $19,498,000. Finally, Vanguard Group Inc. boosted its position in shares of Five Prime Therapeutics by 43.5% in the second quarter. Vanguard Group Inc. now owns 1,472,276 shares of the company’s stock worth $60,877,000 after buying an additional 446,311 shares during the last quarter. 90.12% of the stock is owned by institutional investors.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.
Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.